Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Linking a serotonin transporter polymorphism to vascular smoothmuscle proliferation in patients with primary pulmonary hypertension
Marlene Rabinovitch
Marlene Rabinovitch
Published October 15, 2001
Citation Information: J Clin Invest. 2001;108(8):1109-1111. https://doi.org/10.1172/JCI14205.
View: Text | PDF
Commentary

Linking a serotonin transporter polymorphism to vascular smoothmuscle proliferation in patients with primary pulmonary hypertension

  • Text
  • PDF
Abstract

Authors

Marlene Rabinovitch

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Hypothetical interaction between the pathways regulated by the bone morp...
Hypothetical interaction between the pathways regulated by the bone morphogenetic protein receptor ligands and the serotonin (5-HT) transporter. Here, BMP receptor ligands are proposed to suppress transactivation of genes associated with smooth muscle proliferation by maintaining transcription factors (TF) bound to Smad proteins. Activation of the 5-HT transporter is normally antagonized by this pathway unless BMP receptor ligands are mutated or there is a polymorphism of 5-HT allowing for overexpression.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts